We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eisai Presents Data from Epilepsy Studies of Zebinix and Fycompa
Eisai Presents Data from Epilepsy Studies of Zebinix and Fycompa
Eisai presented data from two Phase III studies of adjunctive therapies for epilepsy—one evaluating the non-inferiority of Zebinix compared to carbamazepine, and an open-label extension study of long-term Fycompa, which demonstrated sustained seizure control for up to two-and-a-half years. The two studies were presented at the European Congress on Epileptology.